Spots Global Cancer Trial Database for penile
Every month we try and update this database with for penile cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Immune Therapy of HPV-induced Cancers | NCT01462838 | HPV-induced Can... | P16_37-63 | 18 Years - | Oryx GmbH & Co. KG | |
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04084951 | Adult Solid Tum... | SQZ-PBMC-HPV Atezolizumab Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
Immune Therapy of HPV-induced Cancers | NCT01462838 | HPV-induced Can... | P16_37-63 | 18 Years - | Oryx GmbH & Co. KG | |
INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue | NCT04574427 | Head and Neck C... Penile Cancer | 18 Years - | The Netherlands Cancer Institute | ||
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT05357898 | Adult Solid Tum... | SQZ-eAPC-HPV Pembrolizumab | 18 Years - | SQZ Biotechnologies |